Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities.

Doe, Chris; Bentley, Ross; Behm, David J; Lafferty, Robert; Stavenger, Robert; Jung, David; Bamford, Mark; Panchal, Terry; Grygielko, Eugene; Wright, Lois L; Smith, Gary K; Chen, Zunxuan; Webb, Christine; Khandekar, Sanjay; Yi, Tracey; Kirkpatrick, Robert; Dul, Edward; Jolivette, Larry; Marino, Joseph P; Willette, Robert; Lee, Dennis; Hu, Erding

Doe, Chris; Bentley, Ross; Behm, David J; Lafferty, Robert; Stavenger, Robert; Jung, David; Bamford, Mark; Panchal, Terry; Grygielko, Eugene; Wright, Lois L; Smith, Gary K; Chen, Zunxuan; Webb, Christine; Khandekar, Sanjay; Yi, Tracey; Kirkpatrick, Robert; Dul, Edward; Jolivette, Larry; Marino, Joseph P; Willette, Robert; Lee, Dennis; Hu, Erding.

Affiliation

Doe C; Department of Investigational Biology, Centres of Excellence for Cardiovascular Urogenital Drug Discovery, Discovery Research, GlaxoSmithKline Pharmaceuticals Inc., King of Prussia, PA 19406, USA.

J Pharmacol Exp Ther ; 320(1): 89-98, 2007 Jan.

Article de En | MEDLINE | ID: mdl-17018693

Sujet(s)

Recherche sur Google

Ajouter à My VHL

Imprimer

XML

PubMed Links

Collection: 01-internacional Base de données: MEDLINE Sujet principal: Oxadiazoles / Vasodilatateurs / Protein-Serine-Threonine Kinases / Protéines et peptides de signalisation intracellulaire / Inhibiteurs de protéines kinases / Imidazoles / Anti-inflammatoires Type d'étude: Prognostic_studies Limites: Animals / Humans / Male Langue: En Journal: J Pharmacol Exp Ther Année: 2007 Type de document: Article Pays d'affiliation: États-Unis d'Amérique

Recherche sur Google

Ajouter à My VHL

Imprimer

XML

PubMed Links